Angle upbeat on recent research using 'Parsortix'
12th May 2020 08:58
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).
Read moreAngle works with skeleton R&D crew during lockdown
28th Apr 2020 10:03
(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
Read moreAngle UK, US, Canada operations 'severely disrupted' by Covid-19
31st Mar 2020 09:40
(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.
Read moreAngle upbeat on recent Parsortix research out of Italy
27th Feb 2020 12:42
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.
Read moreAngle upbeat on German research into 'Parsortix'
17th Feb 2020 15:25
(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.
Read moreAngle upbeat on research into Parsortix with melanoma patients
11th Feb 2020 07:41
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.
Read moreAngle upbeat on patent grant for prostate cancer blood assessment
4th Oct 2019 15:17
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.
Read moreAngle initiates main phase of ovarian cancer clinical study
29th Aug 2019 09:12
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.
Read moreAngle looks to strengthen balance sheet and extend runway via placement
25th Jun 2019 08:16
(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.
Read moreAngle upbeat on recent cancer research results
21st Jun 2019 15:26
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.
Read moreAngle reveals positive results from latest Parsortix study
31st May 2019 09:53
(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.
Read moreAngle's Parsortix system used in more groundbreaking research
26th Apr 2019 12:48
(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.
Read moreAngle's Parsortix to be used in new Greece study
12th Apr 2019 15:25
(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).
Read moreAngle completes enrolment in Parsortix breast cancer study
7th Mar 2019 09:35
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.
Read moreAngle client demonstrates new use for 'Parsortix' system
25th Feb 2019 10:51
(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.
Read more